Differences in the Prognosis according to the Periods of Diagnosis in Ulcerative Colitis

Chae, Hyun Beom; Jung, Yoon Suk; Park, Dong I.L.; Lee, Chang Kyun; Huh, Kyu Chan; Shin, Jeong Eun; Kim, Jae H.ak; Kim, You S.un; Jung, Yunho; Jung, Sung Ae; Song, Hyun Joo; Jang, Hyun Joo; Hong, Sung Noh; Kim, Young H.o.

doi:10.4166/kjg.2014.64.2.93

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…구에 사용된 자료의 특성상 질환의 중등도를 파악할 수는 없 지만 5-ASA의 단독요법 처방이 약 55%로 가장 높은 것으로 보아 경도-중등도 궤양성 대장염의 환자 수가 가장 많을 것으 * 이 오히려 낮았으며 범결장염에서는 통계적으로 유의한 결과 를 도출하지 못했다. 타 연구에서는 병변이 넓은 범결장염에 서 전신작용 스테로이드 처방이 더 잦다는 경향이 보고되었다 19). …”

unclassified

Patterns of Ulcerative Colitis Treatments and Factors Affecting the Prescribing of Systemic Corticosteroid using Health Insurance Claims Database

Kim

Park

Shin

2020

Korean J Clin Pharm

View full text Add to dashboard Cite

Objective: To analyze the prescription patterns for the treatment of ulcerative colitis (UC) and to investigate factors co-occurring with systemic corticosteroid use. Methods: We used patient-level data from Korean National Health Insurance claims database to identify patients diagnosed with UC (ICD-10 code : K51) and their medications prescribed for UC between January 1 and Decemeber 31, 2017. We found that medications for UC treatment were 5-aminosalicylic acid (5-ASA), immunomodulators, biologics, and corticosteroids. We presented the prescription pattern according to the sex, age group, type of health insurance, site of UC, type of medical institution, and concomitant medication. To evaluate factors associated with prescription of systemic corticosteroids for UC, we used a multivariate logistic regression model to estimate adjusted odds ratios (aORs) and their 95% confidence intervals (CIs). Results: Of 1,469 UC patients, 74.5% used 5-ASA and 15.2% used systemic corticosteroids. 5-ASA constituted 77.5% of all prescriptions and systemic corticosteroids accounted for 13.1%. The most widely used therapy was 5-ASA monotherapy (54.8%), followed by a double therapy with 5-ASA and immunomodulators (8.2%) or 5-ASA and systemic corticosteroids (7.2%). Systemic corticosteroids were more likely to be prescribed with immunomodulators (aOR=1.88, 95% CI=1.54-2.28) and biologics (aOR=2.82, 95% CI=2.28-3.50) than without them. Conclusions: We found that 15.2% of UC patients were prescribed with a systemic corticosteroid, which is less than reported previously. Systemic corticosteroids were more likely to be prescribed with immunomodulators and biologics.

show abstract

unclassified

Patterns of Ulcerative Colitis Treatments and Factors Affecting the Prescribing of Systemic Corticosteroid using Health Insurance Claims Database

Kim

Park

Shin

2020

Korean J Clin Pharm

View full text Add to dashboard Cite

show abstract

Differences in the Prognosis according to the Periods of Diagnosis in Ulcerative Colitis

Abstract: Infliximab might play an important role for the treatment of steroid-refractory UC. Well-designed prospective trials based on the efficacy and safety of infliximab are required in the future.

Cited by 1 publication

References 16 publications

Patterns of Ulcerative Colitis Treatments and Factors Affecting the Prescribing of Systemic Corticosteroid using Health Insurance Claims Database

Patterns of Ulcerative Colitis Treatments and Factors Affecting the Prescribing of Systemic Corticosteroid using Health Insurance Claims Database

Contact Info

Product

Resources

About